Last reviewed · How we verify

NAFT600 (pediatric) — Competitive Intelligence Brief

NAFT600 (pediatric) (NAFT600 (pediatric)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antifungal (allylamine). Area: Dermatology.

marketed Topical antifungal (allylamine) Squalene epoxidase (fungal) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

NAFT600 (pediatric) (NAFT600 (pediatric)) — Merz North America, Inc.. NAFT600 is a botulinum toxin product used to reduce muscle contractions and treat movement disorders in pediatric patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NAFT600 (pediatric) TARGET NAFT600 (pediatric) Merz North America, Inc. marketed Topical antifungal (allylamine) Squalene epoxidase (fungal)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antifungal (allylamine) class)

  1. Merz North America, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NAFT600 (pediatric) — Competitive Intelligence Brief. https://druglandscape.com/ci/naft600-pediatric. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: